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Background: Changes in tryptophan metabolism 
are associated with various diseases. 
Results: A comprehensive model of human 
tryptophan metabolism was constructed 
and verified with existing experimental data. 
Conclusion: The subtle balance of tryptophan 
derivatives required for proper brain function is 
sensitive to alterations in peripheral tissues.  
Significance: The model is applicable as a 
diagnostic tool to study disease related changes 
in tryptophan metabolism. 
SUMMARY 
Tryptophan is utilised in various metabolic 
routes including protein synthesis, serotonin 
and melatonin synthesis and the kynurenine 
pathway. Perturbations in these pathways 
have been associated with neurodegenerative 
diseases and cancer. Here, we present a 
comprehensive kinetic model of the complex 
network of human tryptophan metabolism, 
based upon existing kinetic data for all 
enzymatic conversions and transporters. By 
integrating tissue-specific expression data, 
modelling tryptophan metabolism in liver and 
brain returned intermediate metabolite 
concentrations in the physiological range. 
Sensitivity and metabolic control analyses 
identified expected key enzymes to govern 
fluxes in the branches of the network. 
Combining tissue-specific models revealed a 
considerable impact of the kynurenine 
pathway in liver on the concentrations of 
neuroactive derivatives in the brain. 
Moreover, using expression data from a 
cancer study predicted metabolite changes 
that resembled the experimental observations. 
We conclude that the combination of the 
kinetic model with expression data represents 
a powerful diagnostic tool to predict 
alterations in tryptophan metabolism. The 
model is readily scalable to include more 
tissues, thereby enabling assessment of 
organismal tryptophan metabolism in health 
and disease.                                                                   
Tryptophan metabolism plays a number of 
important roles in human physiology. It 
participates in the regulation of growth, moods, 
sleep-wake cycles and immune responses. In 
addition to being an essential amino acid, 
tryptophan is the precursor of important 
molecules such as serotonin, melatonin and 
NAD, and is converted into several neuroactive 
compounds on its route to these products. 
Imbalances in tryptophan metabolism have been 
associated with neurological diseases such as 
Parkinson’s (PD)(1), Alzheimer’s (AD)(2), and 
Huntington’s disease (HD)(3) as well as 
gastrointestinal disorders (4). It has also been 
shown that some types of cancers exhibit 
alterations of tryptophan utilisation which enable 
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them to evade the immune responses of the host 
(5-8). 
Following carrier-mediated uptake into cells, 
tryptophan can be used as a substrate for six 
different reactions thereby entering the 
individual branches of tryptophan metabolism 
(Figure 1). The kynurenine and serotonin 
pathways are the two most important branches 
with regard to the formation of bioactive 
intermediates. The fate of tryptophan utilisation 
is tissue-specific. Most dietary tryptophan is 
metabolised in the liver and most of the serotonin 
is synthesised in the gut, while many of the 
intermediate compounds are important in the 
brain (9,10). Given the rather complex network 
of reactions and the tissue specificity of 
tryptophan metabolism, pathological shifts of 
tryptophan metabolite concentrations (i.e. in 
blood plasma) do not readily indicate the 
underlying alterations in enzyme expressions or 
activities. Therefore, a comprehensive 
mathematical model could provide a predictive 
tool that would facilitate the identification of 
potential pathological changes in tryptophan 
metabolism. 
One particular complication that needs to be 
taken into account when building a kinetic model 
of tryptophan metabolism is that several enzymes 
in the network have rather low substrate 
selectivity and therefore catalyse reactions in 
more than one branch. That is, various 
metabolites arising in different branches of the 
network compete for the active site of the same 
enzyme. For example, indoleamine-pyrrole 2,3-
dioxygenase (IDO) uses L-tryptophan (Trp), 5-
hydroxy-tryptophan (5hTrp), 5-
hydroxytryptamine (serotonin), and N-acetyl-5-
methoxytryptamine (melatonin) as substrates (cf. 
Figure 1). Other enzymes that use multiple 
substrates in the pathway include aromatic L-
amino acid decarboxylase (DDC), 
arylformamidase (AFMID), kynureninase 
(KYNU) and kynurenine aminotransferase 
(KAT). Similarly, L-kynurenine, an intermediate 
product of the kynurenine pathway, is a large 
neutral amino acid that can be transported across 
the cell membrane using the same transporters as 
tryptophan (11). Since uptake of tryptophan has 
been suggested to be rate-limiting for its cellular 
metabolism (12), competition between L-
kynurenine and tryptophan for membrane 
transport could also have significant impact on 
the metabolic outcome. These complex 
interactions are difficult to assess biochemically 
and constitute another important motivation for 
using a modelling approach to study the pathway 
dynamics in health and disease.  
Metabolic control analysis (MCA) (13-15) has 
proved to be a powerful mathematical approach 
to assess pathway dynamics. MCA calculates the 
distribution of control among the enzymes in a 
pathway (13-16), based on the assumption that 
the flux control is shared by all enzymes in the 
pathway. Flux control coefficients (FCCs) 
always sum up to unity, implying that 
concentration (activity) changes of one enzyme 
always affect the control exerted by other 
enzymes. Importantly, within biochemical 
pathways some enzymes may have particularly 
high control (i.e., a high FCC) over the flux 
through the entire pathway. Given their decisive 
role for the “throughput” of the pathway, these 
enzymes are generally considered to be 
promising drug targets. Indeed, MCA has been 
successfully used in pharmacology to identify 
drug targets, but also in biotechnology to 
optimise the production of desired metabolites 
(17,18).  
An often limiting prerequisite for building a 
kinetic model is the availability of the relevant 
kinetic data for all enzymes in the pathway or 
network. Although the exact kinetic mechanisms 
are not known for many enzymes, Michaelis-
Menten kinetics is considered to be a good 
approximation for most enzymes and is 
commonly used to describe reaction rates. The 
parameters required for Michaelis-Menten 
kinetics are the specific half-saturation constant 
or Michaelis-Menten constant (Km), and the 
maximal velocity (Vmax). Vmax can either be 
measured directly as tissue specific activity, or 
calculated from the turnover number (kcat) and 
the enzyme concentration (ET). These kinetic 
parameters, except ET, can be found in kinetics 
databases or in the literature. Due to the 
extensive work that has been done to characterise 
tryptophan metabolism, kinetic data for the 
mammalian enzymes are available for most of 
the enzymes. In fact, kinetic models of the 
kynurenine pathway of tryptophan metabolism, 
limited to the branch synthesising quinolinic acid 
(Quin), have been reported (12,19). However, 
these simple one-branch models do not capture 
the complex dynamics of the multi-branched 
tryptophan metabolic network (20,21). 
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Besides the kinetic data, generation of a suitable 
kinetic model for specific organs or an entire 
organism has another prerequisite: specific 
enzyme activities. Fluxes and their control in 
metabolic pathways vary between tissues, 
because of differential expression of the 
corresponding genes as well as co- and 
posttranslational modifications. Therefore, the 
introduction of scaling factors to adjust the 
activity of each individual enzyme according to 
the actual expression level within a given tissue 
would be required. Such a factor would 
essentially provide a measure for ET. Thus, 
simulation of the dynamics of tryptophan 
metabolism in diseases or upon drug treatment 
would necessitate establishing tissue specific 
flux controls. As several intermediates of 
tryptophan metabolism are known to be 
transported into the blood (22,23), it is 
reasonable to expect that metabolites generated 
in one tissue can affect tryptophan metabolism in 
another. To explore such inter-dependencies 
would additionally necessitate connecting the 
mathematical models established for individual 
tissues assuming blood as “metabolite carrier”. 
In this article, we report the construction of a 
comprehensive kinetic model of mammalian 
tryptophan metabolism which includes kinetic 
data for the enzymes in all known branches of 
the network (Figure 1). The kinetic model was 
integrated with gene expression data from human 
liver and brain, thereby establishing tissue-
specific models, and analysed for control in the 
system using MCA. The simulations returned 
expected steady state flux distributions for these 
tissues validating the applicability of the 
modelling approach in combination with gene 
expression data. We demonstrate the flexibility 
and scalability of the model by combining the 
brain and liver models into a multi-tissue model. 
Finally, the usability of the model for the study 
of diseases is illustrated by applying gene 
expression data from Tuberculosis meningitis 
patients and from a cancer study which resulted 
in the prediction of metabolic changes that 
coincided with those measured in the patients. 
Thus, our model provides a valuable diagnostic 
tool to predict pathological changes of 
tryptophan metabolism based on a limited 
number of clinical measurements.  
METHODS 
A dynamic model of mammalian tryptophan 
metabolism -- The set of reactions involved in 
tryptophan metabolism was obtained from 
KEGG(http://www.genome.jp/kegg/pathway/ma
p/map00380.html) (24). When available, enzyme 
kinetic data was originally retrieved from Brenda 
(http://www.brenda-enzymes.org/) (25), and 
transporter substrate affinities were retrieved 
from Uniprot (http://www.uniprot.org/) (26). The 
original literature cited in the databases was 
reviewed to verify the kinetic values and to make 
sure that measuring conditions were appropriate. 
A few reactions could not be included in the 
model due to lack of kinetic data. Fortunately, 
these reactions are at the end of branches, and 
excluding them does not affect the model. 
Michaelis-Menten kinetics, or modified versions 
thereof, were used for all enzymatic and 
transport reactions, while non-enzymatic 
reactions were modelled using mass action 
kinetics.  
Establishment of a comprehensive model of 
tryptophan metabolism was found to be still 
limited by incomplete experimental data, 
especially with regard to tissue-specific enzyme 
activities (i.e. protein levels), metabolite and 
cofactor concentrations as well as enzyme 
mechanisms. Therefore, we needed to include a 
few simplifications and assumptions as outlined 
below. 
Except for the transport processes, all reactions 
were modelled as irreversible for two reasons. 
First, reactions involving oxygenation, 
acetylation, ring forming, and ring breaking are 
unlikely to be reversed due to their chemical 
nature. Second, potentially reversible reactions in 
the network are all followed by fast non-
enzymatic reactions, which drive the preceding 
enzymatic reaction in the forward direction. 
 Some of the enzymatic reactions are inhibited by 
up- or downstream metabolites such as picolinic 
acid (Pic), Quin, anthralinic acid (AA) and 
kynurenic acid (Kyna) in vitro. However, in all 
cases, the half maximal inhibitory concentrations 
are more than 1000-fold above reported 
physiological concentrations. That is, there is no 
known feedback inhibition of physiological 
relevance and such events were, consequently, 
not included in the model.  
We limited the model by setting all co-substrates, 
including PRPP, NADPH, acetyl-CoA, and 
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oxygen as external metabolites. Their 
concentrations were set to 1 mM (except 
NADPH = 0.03 mM) to not limit the flux. In 
turn, this also implied that kinetic rate laws could 
be modelled as monomolecular reactions. A full 
list of rate laws used is shown in Supplementary 
Table 1.  
The external tryptophan concentration was set to 
5 µM, unless otherwise stated. 
Tissue-specific models of tryptophan metabolism 
– Two different approaches were used to 
generate tissue-specific models. One was based 
on reported enzyme activities measured in tissue 
homogenates, and the other combined measured 
activities of purified enzymes with tissue-
specific gene expression data. 
Tissue activities can be used as a measure for the 
maximum reaction rate Vmax in the Michaelis-
Menten equation: 




where v is the reaction rate, Km is the Michaelis-
Menten (half-saturation) constant, and S is the 
substrate concentration. If enzyme activities were 
lacking for liver, as was the case for MAOA/B, 
TPH1/2, IL4 and protein synthesis, 
measurements from another tissue were scaled to 
liver levels using gene expression data. 
In the alternative approach, purified enzyme 
activities can be used to calculate the enzymatic 
turnover number kcat, which, when multiplied 
with the total enzyme concentration ET, gives 
Vmax: 
Equation 2: 𝑣 =  
𝐸𝑇 × 𝑘𝑐𝑎𝑡 × 𝑆
𝐾𝑚 + 𝑆
 
In most cases, however, tissue-specific enzyme 
concentrations are not available. In contrast, gene 
expression data are available for many tissues, 
and mRNA levels can be used as a crude 
estimate for enzyme concentration: 
Equation 3: 𝑣 =  
𝐹 × 𝑚𝑅𝑁𝐴 × 𝑘𝑐𝑎𝑡 × 𝑆
𝐾𝑚 + 𝑆
 
where mRNA is the measured microarray signal 
(unitless) from gene expression experiments, and 
F is a factor (unit mM) used to convert 
microarray signals to enzyme concentrations. In 
our model F is a global factor, as our model 
assumes that the microarray signals are in a 
linear range, and that the mRNA levels 
correspond linearly to enzyme concentrations. To 
calculate meaningful absolute fluxes and 
metabolite steady state concentrations for 
substrates and products of non-enzymatic 
reactions, F must be determined. In contrast, 
relative fluxes and steady state concentrations of 
substrates and products of enzymatic reactions 
are independent of F. If not stated otherwise, F 
was arbitrarily set to 1 mM, with the implication 
that the simulations returned arbitrary absolute 
fluxes and arbitrary concentrations for substrates 
and products of non-enzymatic reactions. 
Gene expression data sets were obtained from 
Array Express 
(http://www.ebi.ac.uk/arrayexpress/) or Gene 
Expression Omnibus (GEO) 
(http://www.ncbi.nlm.nih.gov/geo/). For the 
tissue simulations replicate arrays were 
combined using the biweight function 
implemented in the gene expression analysis 
software J-Express Pro, to obtain one signal 
value representing the expression for each 
enzyme for a tissue. For the glioblastoma and 
tuberculosis datasets, separate simulations were 
done for each replicate array, and average 
concentrations and standard deviations were 
calculated afterwards. The signal values were 
used directly without further processing. If a 
gene was represented by multiple probes on the 
array the probe with the highest signal was 
chosen. The various data sets are referenced in 
the results section and listed in Supplementary 
Tables 4. The sbml-file of the model generated 
for human liver tryptophan metabolism is 
available in the biomodels database 
(http://www.ebi.ac.uk/biomodels-main/) 
accession number #.  
 
Enzyme competition -- The Michaelis-Menten 
rate law for competitive inhibition of irreversible 
reactions was used for the enzymatic reactions 
when enzymes catalyse more than one reaction: 
Equation 4: 𝑣 =  
𝑉𝑚𝑎𝑥 × 𝑆




where I is the concentration of the competing 
substrate and Ki is the Michaelis-Menten 
constant of the competing substrate. Equation 4 
can be extended to any finite number of 
competitors as shown mathematically by Chou 
and Talaly (27). For the reversible transport of 
tryptophan and L-kynurenine we used a rate law 
for two competing substrates based on steady 
state assumptions (28).  
For the approach using purified enzyme activities 
and gene expression data, Vmax in Equation 4 was 
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substituted with F × mRNA × kcat, as in 
Equation 3. 
Sensitivity Analysis -- Global sensitivity analysis 
was performed with respect to enzyme specific 
Km values and the gene expression data. To be 
able to do global sensitivity analysis within a 
reasonable amount of time and with moderate 
computational power we used the method 
described by Sahle et al. (29). This method is 
based on optimisation of an objective function. 
Two different optimisation algorithms were 
applied (evolutionary programming and particle 
swarm) to make sure that the result were 
independent of the method used. For the 
optimisation based on evolutionary programming 
we used a population size of 40 and 500 
generations. The particle swarm algorithm was 
applied with the default settings (iteration limit 
2000 and swarm size 50).  
Sensitivity to changes in the Km values were 
assessed by searching the parameter space for 
values that would maximise or minimise flux 
control coefficients for 3-hydroxyanthranilic 
(3HAA) oxygenase (HAAO) in the kynurenine 
pathway and DDC in the serotonin pathway. 
Combining the search with an optimisation 
algorithm allows searching the parameter space 
for sets of Km values that leads to optimal 
conditions for the objective function. To limit the 
search space, minimum and maximum values 
were set for each Km parameter. If diverging Km 
parameter values had been found in the literature 
or in BRENDA, the lowest and highest values 
recorded were used as limits. If the available data 
were consistent or only single measurements 
were found, we set ±90% of the model values as 
parameter range.  
Similarly, the sensitivity to changes in gene 
expression values was assessed by searching the 
parameter space for expression values that would 
result in maximum or minimum flux through 
HAAO or DDC. The parameter space for each 
enzyme was limited by the minimum and 
maximum expression value measured for the 
respective genes on the microarrays, across all 
tissues of the data set by Dezso et al (30) (GEO 
accession GDS3113). The parameter search 
space for expression values was huge, and there 
could be several optimal parameter combinations 
that would result in similar maximum and 
minimum fluxes through HAAO and DDC. Each 
optimisation was therefore repeated 20 times to 
get an estimate for the variability of optimised 
expression values. Enzymes with small 
variations of expression values across the 20 runs 
would then be important for obtaining the 
optimised fluxes.  
Software used for analysis and visualisations --
Expression data was formatted using J-Express 
Pro 2012 (31,32). All calculations of fluxes and 
intermediate concentrations were performed with 
the steady state task of COPASI 4.10 (33). The 
sensitivity analysis was performed using the 
metabolic control analysis task and the command 
line version of the software. 
  
RESULTS 
Kinetic model of tryptophan metabolism predicts 
expected flux distribution patterns and 
metabolite concentrations in rat liver--To 
simulate flux distributions and metabolite 
concentrations in the mammalian tryptophan 
pathway we constructed a tissue-specific kinetic 
model (Figure 1). Kinetic data for 29 enzymatic 
reactions and two transporters in the network 
were retrieved from databases (KEGG and 
Brenda) and cross validated with the original 
literature.  Some of the reactions are catalysed by 
different isoenzymes, e.g. L-kynurenine 
aminotransferase (KAT) 1-3 and L-tryptophan 
hydroxylase (TPH) 1-2. Separate reactions were 
added to the model for each isoenzyme, and 
isoenzyme-specific kinetic constants were used if 
available. Each of the two transport reactions for 
tryptophan and L-kynurenine can be carried out 
by two different transporters. Hence, the model 
consists of 35 enzyme-catalysed reactions (set 
irreversible) and 4 reversible transport reactions. 
For those enzymes that catalyse more than one 
reaction in the network, we included competition 
between these reactions. Since the different 
substrates compete for the same active sites of 
these enzymes, one substrate can be seen as 
competitive inhibitor of the others. Therefore, the 
kinetic model included competitive inhibition 
where appropriate (cf. Figure 1). We have 
recently demonstrated that such competition can 
affect both steady state concentrations and the 
dynamic behaviour of metabolic systems (28). 
Initial simulations with the tryptophan metabolic 
model confirmed that the calculated fluxes were 
affected by the inhibition as expected. 
Tryptophan and L-kynurenine were allowed to 
be exchanged with the environment. Since both 
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use the same transporters, competition also had 
to be considered for the exchange reactions. 
To adjust the model according to liver-specific 
enzyme activities, we first tried to make use of 
published studies in which activities were 
measured in rat liver homogenates. Indeed, liver-
specific activities were available for most of the 
reactions. For the remaining reactions, activities 
measured in total extracts from other tissues 
were used in combination with gene expression 
data to scale the specific activities to liver levels 
(33). The predicted flux toward protein synthesis 
was 98.9% relative to tryptophan import, 
suggesting that almost all of tryptophan is used 
for protein synthesis. This prediction is in stark 
contrast to the actual situation, in which little 
dietary tryptophan is used for protein synthesis 
(10). To assess the effect of excluding protein 
synthesis, simulations were performed with a 
variant of the model that excluded tryptophan 
tRNA ligase (WARS). This resulted in increased 
relative fluxes through the kynurenine pathway 
(tryptophan 2,3-dioxygenase, TDO: 21%), 
serotonin pathway (TPH: 29.3%), and interleukin 
4 induced 1 (IL4I1: 47.8%). However, this is still 
far from physiological conditions, where up to 
99% of tryptophan has been reported to be 
degraded through the kynurenine pathway in 
liver (9,10). Furthermore, the calculations 
predicted metabolite concentrations far outside 
the physiological range (e.g. L-kynurenine, 0.053 
µM,3HKyn 2.2nM and serotonin, 0.7 µM; for 
comparison see Table 1). The discrepancy 
between observed and calculated fluxes may be 
due to problems inherent to determining specific 
enzyme activities in tissue homogenates. Most 
likely, such determinations are affected by 
enzyme instability (for example, TDO has a half-
life of only about 2 hours (10)). Moreover, they 
can only to a limited extent account for 
competition between pathways or product 
utilisation in subsequent reactions. Given this 
result, we did not continue building models 
based on enzyme activities measured directly in 
tissues. 
As an alternative approach, we used specific 
activities measured for purified enzymes which 
were available for most enzymes. From these 
activities we calculated the enzymatic turnover 
number, kcat. To estimate the total enzyme 
concentrations, ET, gene expression data (34; 
ArrayExpress accession E-BASE-4) was used as 
described in Methods. Figure 2A shows the 
result (for rat liver) of steady state calculations 
with this model in a simplified figure of the 
tryptophan metabolic pathway. For visualisation 
purposes (here and subsequent figures) only the 
main branch points of the kynurenine and 
serotonin pathways are shown, while the 
simulations are based on the full model.  
Simulations suggested that 94.6% of tryptophan 
are metabolised by TDO in the kynurenine 
pathway, and then split between KAT and KMO. 
These predictions resemble known flux 
distributions for rat liver (9,10). In addition, as 
can be inferred from Table 1, the calculated 
intermediate concentrations for L-kynurenine (L-
Kyn, 1.2 µM) and 3-hydroxy-kynurenine 
(3HKyn, 0.02 µM) are close to the values 
measured in rat plasma. Consequently, kinetic 
modelling using turnover numbers in conjunction 
with measured mRNA abundance of the 
corresponding genes to adjust for gene 
expression appeared to reflect the actual 
physiological situation rather accurately. 
Importantly, this approach does not rely on 
tissue-specific activities and therefore can be 
readily used to generate models for other tissues. 
The same turnover numbers will apply and ET 
values are adjusted by tissue-specific expression 
data. 
 
Tissue-specific flux distributions are similar in 
human and rat – To compare predicted 
metabolite concentrations and relative fluxes in 
different tissues of different species, we created 
additional models for rat cortex, human liver, 
and human brain. ET in the different tissues were 
estimated using gene expression datasets from rat 
(34; ArrayExpress accession E-BASE-4) and 
human (30; GEO accession GDS3113).  The 
calculated concentrations and fluxes are shown 
in Figure 2. Interestingly, the models predict that 
fluxes in rat and human liver are similar, but 
different from fluxes in rat cortex and human 
brain. Moreover, rat cortex fluxes are 
comparable to those of the human brain. In 
cortex and brain, the flux is shifted from the 
kynurenine pathway (IDO/TDO) towards the 
serotonin pathway (TPH). This results in higher 
concentrations of serotonin in the brain tissues 
and lower concentrations of the potentially 
neurotoxic metabolites 3HKyn and 3HAA. The 
latter is also reflected in the flux ratios between 
KAT and KMO, which is 1.5-2.1 in liver and 11-
19.4 in brain. The relative flux towards protein 
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synthesis (WARS) is predicted to be 10% and 
30.5% in rat cortex and human brain, 
respectively, which is higher than expected. 
To assess the validity of the predicted metabolite 
concentrations, we performed simulations using 
a range of tryptophan concentrations. The total 
tryptophan concentration in blood has been 
reported to be in the range from 39.7-91 µM 
(12,35-37), but with only 10-18% freely 
available to the cells (10,37,38). Hence, the 
range for the fixed concentration of tryptophan 
used in the simulations of liver metabolism was 
4-16 µM. The tryptophan concentration reported 
for cerebrospinal fluid (CSF) and used for 
simulations of brain metabolism in Table1 was 
somewhat lower (1.3-2.6 µM, (37)). Calculated 
metabolite concentrations for human liver and 
brain, along with measured concentrations from 
blood plasma and CSF are shown in Table 2.  
To assess to what extent the results from model 
simulations depended on the accuracy of the 
kinetic values, sensitivity analysis was 
performed. This was done by varying the Km 
values (Supplementary Tables 2 and 3) and the 
expression data (Supplementary Figure 1), see 
materials and methods for details. The results 
from the sensitivity analysis showed that some 
Km values could be varied considerably without 
noticeably affecting simulation outcomes, while 
changing Km values for other enzymes 
significantly affected the outcome. Similar 
observations were made when the numbers for 
the expression data were varied. Generally, 
variation in the values for enzymes at branch 
points resulted in greater variation of simulation 
results. Therefore, it appears particularly 
important to accurately determine the kinetic 
constants and protein concentrations for the 
enzymes at branch points. 
 
Pathway control is distributed differently in 
brain and liver -- Metabolic control analysis was 
used to analyse the distribution of control in 
tryptophan metabolism in human liver and brain 
(Figure 3). The control of flux through the 
reaction converting 5-hydroxytryptophan 
(5HTrp) into serotonin, catalysed by aromatic L-
amino acid decarboxylase (DDC), was used as a 
measure for the control of the serotonin pathway. 
Similarly, the control of the flux through the 
reaction converting 3-hydroxyanthranilate 
(3HAA) into 2-amino-3-carboxymuconate 
semialdehyde (Acms), catalysed by 3-
hydroxyanthranilate 3,4-dioxygenase (HAAO) 
was used as a measure for the control of the 
kynurenine pathway. In liver, the flux control for 
the serotonin pathway seems to be shared 
between TPH, TDO and the transport of 
tryptophan with flux control coefficients (FCC) 
of 0.99, -0.96 and 0.91 respectively. Sensitivity 
analysis showed that these control coefficients 
were rather robust as they varied little when 
changing kinetic or expression values. In brain, 
TPH was the major control point for serotonin 
synthesis with an FCC of 0.98. In the kynurenine 
pathway, kynurenine 3-monooxygenase (KMO) 
was a major control point in both liver (0.88) and 
brain (0.99). Transport of tryptophan also had 
control in liver (0.93), while TDO, IDO, 
transport of tryptophan and transport of L-
kynurenine had control in brain with FCCs of 
0.55, 0.33, 0.22, and -0.82 respectively. 
Additionally, kynurenine-aminotransferases 
(KATs) exert some control in the brain (-0.35). 
In summary, the analyses showed that the flux 
control was distributed differently in brain and 
liver. The flux through the kynurenine pathway 
in liver is chiefly controlled by KMO, whereas in 
brain flux control is shared among several 
enzymes. 
Building a multi-tissue model -- Simulations of 
tryptophan metabolism in individual tissues have 
great value, for example, to predict or understand 
pathological alterations. However, several 
intermediates of tryptophan metabolism undergo 
exchange between tissues and blood. Therefore, 
it is important to consider the possibility that 
tryptophan metabolism in one tissue can 
influence that in other tissues. 
Our modelling approach permitted to combine 
the simulations for human liver and brain and to 
connect them via a “blood compartment” 
mediating the exchange of metabolites between 
these tissues (Figure 4). We assumed tissue 
volumes to be 1.5 and 1.35 litres for liver and 
brain, respectively, and 6 litres for blood. 
Tryptophan and L-kynurenine were the only 
metabolites that were allowed to be exchanged 
between these tissues and blood. Other 
intermediates are known to be transported into 
the blood (22,23), but it is uncertain whether they 
can cross the blood brain barrier in significant 
amounts.  
The most notable change in calculated brain 
metabolite concentrations, as a result of 
connecting the two tissues, was elevated levels of 
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kynurenine pathway metabolites (Figures 4A). 
This is caused by a decrease in the net outflow of 
L-kynurenine from the brain, as liver maintains a 
high blood concentration of L-kynurenine. These 
simulations thus indicate that liver tryptophan 
metabolism contributes to the generation of both 
neuroprotective and neurotoxic intermediates in 
the brain. Interestingly, Zwilling et al. (39) 
showed that pharmacological inhibition of KMO 
in peripheral tissues with the pro-drug JM6 
provided protection against neurodegeneration in 
mouse models of Huntington’s and Alzheimer’s 
disease, even though JM6 cannot cross the 
blood-brain barrier. Although not statistically 
significant, they also reported a small increase in 
3HKyn and Quin. We used our multi-tissue 
model to simulate these experiments by limiting 
the activity of KMO in liver to 10% of its 
original value. To allow calculation of 
meaningful metabolite steady state 
concentrations for substrates and products of 
non-enzymatic reactions, including Quin, the 
model was scaled using the F factor. The 
reported KMO activity measurements for control 
mice (39) was used to calculate F, and was found 
to be 7.29e-10 mM. Using this scaled model we 
can reproduce the slight increase in 3HKyn and 
Quin concentrations observed in the experiments, 
see Figure 4B and C. The largest change in 
treated mice, however, was observed with 
kynurenate (Kyna). Unfortunately, our model is 
unable to calculate steady state concentrations 
for Kyna, as it is an external metabolite due to 
lacking information about transport and 
excretion of Kyna. However, our simulations 
showed a 14% increase in the Kyna production 
rate (KAT flux), which qualitatively agrees with 
the experimental data. In conclusion, our 
simulations resembled to a large extent the 
experimental results reported by Zwilling et al. 
(39). 
Simulation of pathological alterations of 
tryptophan metabolism -- Several cancers are 
known to upregulate TDO or IDO leading to 
elevated L-kynurenine and decreased Trp 
concentrations. Opitz et al. (7) showed that L-
kynurenine binds to the aryl hydrocarbon 
receptor which suppresses anti-tumour immune-
responses and promotes cancer survival. We 
simulated a two-fold upregulation of TDO in our 
isolate brain model, and our calculations showed 
an increase of L-kynurenine of 49.9%. Next, we 
used microarray data from a brain cancer study 
(40; GEO accession GSE15824) to adjust the 
concentrations of enzymes in the same brain 
model. The results are displayed in Figure 5 and 
show a decrease in steady state concentration of 
Trp, and an increased of L-Kyn in secondary 
glioblastoma compared to primary glioblastoma 
and healthy brain samples. The great variation 
within each group reflects the variations in gene 
expression data. Nevertheless, there was a clear 
correlation between the calculated concentration 
of L-kynurenine and the gene expression levels 
of IDO and TDO (correlation coefficients were 
0.74 and 0.96, respectively) across all healthy 
and cancer samples in the data set, confirming 
the observations by Opitz et al (7).  
Finally, we integrated gene expression data from 
a Tuberculosis meningitis (TBM) profiling study 
of human brains (GEO accession GSE23074) 
with the isolate brain model and calculated 
steady state concentrations of the metabolic 
intermediates for brains of both infected 
individuals (n=5) and normal controls (n=4). Our 
model simulations predicted a slight decrease in 
serotonin concentrations as well as a slight 
increase in the intermediate concentrations of the 
kynurenine pathway for infected individuals. 
Moreover, our simulations predict that the ratio 
of mean fluxes through KAT/KMO decreased by 
28.1% in TBM patients. O’Connor et al. (41) 
showed that induction of IDO by Bacille 
Calmette-Guerin (a pathogen widely used as a 
vaccine against tuberculosis) is responsible for a 
depressive-like behaviour in mice. They 
proposed that a shift to a less favourable ratio of 
neuroprotective and neurotoxic kynurenine 
derivatives could contribute to a depressive 
phenotype. Our analyses lend support to such a 
metabolic shift as a diminished KAT/KMO ratio 
would, for example, lead to higher 
concentrations of neurotoxic quinolinic acid 
while diminishing protective kynurenate 
concentrations.   
DISCUSSION 
The present study provides the most 
comprehensive kinetic model of tryptophan 
metabolism to date. It includes all branches of 
this complex network, thereby enabling the 
detection of interdependencies between the 
individual pathways. Moreover, inclusion of 
nearly all reactions of the network into the 
calculations makes it possible for the first time to 
generate realistic predictions for intermediate 
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metabolite concentrations and flux distributions 
of tryptophan metabolism in different tissues. 
This possibility has arisen from the successful 
adjustment of individual enzyme activities 
according to tissue-specific expression of the 
corresponding genes. 
Intuitively, it would appear that using specific 
enzyme activities measured in tissue extracts 
would provide the most accurate values. 
However, our results indicate that, at least in 
liver, the application of these data to the generic 
model returns flux distributions that do not 
reflect the physiological situation. Inaccuracies 
of measurements (for example, due to enzyme 
instabilities), even if only for a few enzymes, are 
likely to affect the outcome of the simulations for 
such a complex metabolic network. Indeed, our 
sensitivity analyses revealed that this would be 
the case, particularly when it concerns enzymes 
at branch points, such as TDO.  
Even though we are well aware that gene 
expression (mRNA levels) does not necessarily 
correlate with the amount of the corresponding 
protein, we used such data to scale our kinetic 
model to tissue-specific enzyme activities. Using 
this approach, the calculations of tryptophan 
metabolism for both liver and brain returned flux 
distributions and metabolite concentrations that 
closely resemble physiological values (35-37). 
Our mathematical approach also produced results 
for diseased tissues, such as cancers or 
infections, which predict changes similar to those 
reported (7,39). According to these results, the 
possibility exists that the ratio between 
corresponding mRNA and protein levels, at least 
for the key enzymes, is similar within the 
network of tryptophan metabolism. 
Unfortunately, there are no quantitative 
proteomics data available to verify this notion. In 
fact, this is the reason why we needed to resort to 
gene expression data in the first place, rather 
than using tissue protein levels.  
Another interesting observation is the 
correspondence of our predictions with measured 
values, despite the absence of any regulatory 
components, such as allosteric regulation and 
product inhibition, in our model. Indeed, the 
concentrations required to achieve known 
inhibitory effects of metabolites on enzymes of 
tryptophan metabolism are far beyond 
physiological values. Nevertheless, we cannot 
exclude the existence of hitherto undiscovered 
regulatory mechanisms within this network. 
However, expression of the genes encoding 
TPH1/2, TDO, IDO and IL4, are known to be 
regulated by melatonin, Trp/L-Kyn and upon 
inflammation respectively. Thus, it appears as 
though tryptophan metabolism could be 
primarily regulated through enzyme abundance 
rather than by allosteric mechanisms or product 
inhibition. Thus, the inclusion of gene expression 
data into our model has the further advantage 
that it would account for this type of regulation. 
As for any metabolic model, an unequivocal 
verification would, however, only be achieved, if 
simultaneously metabolomics, quantitative 
proteomics and expression analyses were 
conducted in several organs from the same 
organism.  
Therefore, it is important to note that comparison 
of values obtained from the model with those 
from the literature has limitations, because 
measurements have been made in different 
samples including blood, serum or cell culture 
and may vary considerably depending on the 
experimental conditions  (37). 
Integration of expression data with a kinetic 
model has been successfully done for a model of 
the citric acid cycle in Escherichia coli and 
Mycobacterium tuberculosis (33). In this case, 
fold change values were calculated from gene 
expression data and used to scale the Vmax values 
obtained from published literature, to simulate 
different conditions. To our knowledge, our 
approach to use turnover numbers and expression 
values has so far not been used for kinetic 
modelling.  
Gene expression data is also regularly used in 
flux balance calculations to adjust the flux 
capacity of a reaction (see e.g., 42). In contrast to 
flux balance analysis, we apply additional 
constraints which are the steady state 
requirement and the measured metabolite 
affinities. One problem of using gene expression 
data directly, as we have done in most of our 
models, is that the calculated absolute flux values 
are arbitrary, and only relative fluxes can be 
meaningfully compared to experimental data. 
However, as we have shown in simulations of 
KMO inhibition experiments in mice, the model 
can be scaled to produce absolute flux values, 
provided that experimentally measured enzyme 
activities are available from a reference tissue. In 
addition to absolute fluxes, such a scaled model 
also permits the calculation of steady state 
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concentrations for substrates and products of 
non-enzymatic reactions, such as quinolic acid. 
The metabolic control analyses we conducted 
suggested that TPH and KMO are major control 
points in both liver and brain, along with TDO or 
IDO, depending on the tissue. This was not 
surprising. Indeed, all these enzymes have 
emerged as promising drug targets based on 
biochemical studies of tryptophan metabolism. 
TPH is targeted for irritable bowel syndrome 
(43), KMO is targeted for Huntington's disease 
and may be a promising target for several 
neurodegenerative diseases (44). TDO inhibition 
is regarded as a strategy for cancer suppression 
(45). Our analyses further demonstrated that the 
metabolite transporters also have significant 
control over tryptophan metabolism. Targeting 
the transporters, however, is likely to have 
adverse effects, because they are also required 
for the transport of other amino acids (11). All in 
all, the control analyses showed that there are 
several control points in tryptophan metabolism, 
particularly in the brain. Therefore, mutations 
that affect the activity of these enzymes to small 
extent when measured in isolation may still have 
considerable effects on the network as a whole. 
That is, there could be seemingly harmless 
variations in individual enzyme structures that 
could account for tryptophan metabolism being 
involved in many different diseases. 
Another important outcome of the present study 
is the demonstrated potential to scale the kinetic 
models of individual organs into a 
comprehensive multi-tissue model. We have 
tested this possibility by combining the models 
generated for liver and brain and connecting 
them via blood as a metabolite carrier for 
tryptophan and L-kynurenine. Even though this 
model was based on relatively simple 
assumptions for tissue volumes and constrained 
to only two permeable metabolites, the 
calculations indicated that the tissues interact 
metabolically as indicated by modified fluxes 
(Figure 4). This notion became especially 
apparent, when simulating liver KMO inhibition 
by JM6 which was experimentally investigated 
recently (39). The inhibitor was administered 
orally, and showed positive effects in 
Huntington’s disease, despite the fact that the 
inhibitor is unable to cross the blood-brain 
barrier. The protection was ascribed to increased 
levels of kynurenate in the brain. Our simulations 
showed elevated levels of L-kynurenine and 
increased kynurenate production rates, in line 
with the experimental results. Moreover, the 
simulations also reproduced the experimentally 
measured slight increased levels of the 
neurotoxic compounds 3HKyn and Quin. Despite 
the promising results of our simulations, the 
development of an adequate multi-tissue model 
would require inclusion of more peripheral 
tissues, more precise estimation of tissue 
volumes and availability of data regarding the 
presence and kinetics of transporters for other 
metabolites of the network. 
The flexibility and scalability of our approach 
opens up wide-ranging possibilities for studying 
the dynamics of tryptophan metabolism in 
different diseases. For example, increased levels 
of L-kynurenine have been observed in cancers 
and may be part of the mechanism by which 
tumours evade immune responses (7). As a case 
study, we integrated gene expression data from 
brain cancers with our kinetic model. The results 
indicated great variability in the levels of this 
metabolite, which actually fits well with 
measurements in glioblastomas (7). In our 
simulations, the L-kynurenine concentration 
correlated with the expression level of TDO, as 
would have been expected from the experimental 
data. 
In conclusion, a comprehensive and robust 
kinetic model of mammalian tryptophan 
metabolism has emerged from the present study. 
Based on comparison with reported biochemical 
measurements, we conclude that the model 
provides unprecedented accuracy in describing 
the actual state of tryptophan metabolism in 
tissues. Since it can be easily adjusted to 
essentially any tissue using readily available 
gene expression data, the model has the potential 
to become widely used as a predictive and 
diagnostic tool, considering that tryptophan 
metabolism is affected in a broad range of 
diseases. We envision the possibility that, once it 
can be scaled to a reliable multi-organ model, 
metabolite measurements in blood may provide 
sufficient information to deduce organ-specific 
alterations in tryptophan metabolites. Moreover, 
the principal approach of integrating a kinetic 
model with mRNA levels of the corresponding 
genes can be readily adopted for other metabolic 
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TABLES 
TABLE1 
Comparison between calculated and experimentally measured concentrations of tryptophan pathway 
metabolites in rat. The rat liver and cortex models were built using averaged tissue specific gene 
expression data to scale enzyme specific activities. The calculated concentration ranges were obtained 
by varying the amount of tryptophan used as input for models. For liver the tryptophan range was 
based on human blood values, as rat blood concentrations are of limited availability. They do, 
however, appear to be in the same range (36,46). The concentration of free tryptophan available for 
uptake in liver corresponds to 10-20% of the total tryptophan measured (39.7 -91 µM; (35,37)) and 
hence the input range was set to 4 – 16 µM.  For the rat cortex model a tryptophan  range of 0.9 – 2.6 
µM, resembling human CSF concentrations (37), was used directly. 









Cerebrospinal fluid References 
Seretonin nM 4.1 – 10.8 6.0 – 16.2 - -  
L-Kyn µM 1.0 – 3.0 0.035 – 0.11 1.4 –  3.8  0.032 – 0.047  (23,36,46) 
3HKyn nM 19,8– 58.3 0.9 – 5.0 39.5 – 63.3  - (36,46) 




Comparison between calculated and experimentally measured concentrations of tryptophan pathway 
metabolites in human.  The human liver and brain models were built using averaged tissue specific 
gene expression data to scale enzyme specific activities. The calculated concentration ranges were 
obtained by varying the amount of tryptophan used as input to the models.  For the liver model the 
tryptophan range was set to 4 – 16 µM (see Table 1 legend) and for the brain model the reported 
concentration range of 0.9 – 2.6 µM measurements in CSF (37) was used. The human metabolome 
database (36) and the review by Chen et al. (37) each summarise several independent studies reporting 
metabolite measurements. The total number of original articles is indicated in parenthesis. The most 
comprehensive dataset comprises measurements from 94 healthy persons and the range reported 
represents the 5th and 95th percentile (35). 











Seretonin nM 0.1 – 0.2 0.6 – 6.4 - 0.6–12 (5) (36) 
L-Kyn µM 2.2 – 6.9 0.08 – 0.23 0.7 – 4.32 (19) 0.027–0.061(9) (35-37) 
3HKyn nM 9.8 – 30.4 0.9 – 2.6 12.5 – 383 (2) - (35,37) 
3HAA nM 2.7 – 8.3 0.06 – 0.2 7.9 – 209 (3) - (35,37) 
16 
TABLE3 
Calculation of tryptophan pathway metabolite concentrations in Tuberculosis meningitis patients. 
Model for healthy individuals and TBM patients were constructed using expression data (GEO 
accession GSE23074) to scale enzyme specific activities. For each sample a separate model was 
generated and the concentrations were calculated with a fixed tryptophan concentration of 1.75 µM as 
input.  This concentration resembles the medium concentration for human CSF found in the literature 
(37).  
 
Metabolite Unit Normal TBM 
Seretonin nM 21±11 19±6 
L-Kyn µM 0.13±0.08 0.19±0.05 
3HKyn nM 3.4±2.4 4.8±3.2 
3HAA nM 0.22±0.11 0.31±0.14 
KAT/KMO  5.7±2.6 4.1±2.0 
 
FIGURE LEGENDS 
FIGURE 1  
Overview of the tryptophan metabolic pathway. The two most important branches of this pathway are 
the serotonin pathway and the kynurenine pathway. These have been marked by gray backgrounds. 
Metabolites are shown in ellipses, and directions of reactions are shown by arrows with the enzyme 
names next to them. Enzyme names are written in italic upper case letters. Arrows without enzyme 
names are non-enzymatic reactions. Dotted arrows are reactions for which kinetic data were missing. 
The double vertical lines on the left hand side depict plasma membrane, and the bi-directional arrows 
crossing it show the transport of tryptophan and L-kynurenine. The names of the transporters are 
written next to the arrows. Abbreviations for the metabolites are as follows: Trp, tryptophan; Fkyn, 
formyl-kynurenine; L-Kyn, L-kynurenine; Kyna, Kynurenic acid; AA, anthranilic acid; FAA, formyl-
AA; 3HKyn, 3-hydroxy-kynurenine; Xanth, Xanthurenic acid; 3HAA, 3-hydroxy AA; Acms, 2-
amino-3-carboxymuconate semialdehyde; Am6sa, 2-aminomuconate semialdehyde; Pic, picolinic 
acid; Quin, quinolinic acid; Cin, cinnabarinic acid; 5HTrp, 5-hydroxy-tryptophan; Trypta, tryptamin; 
MTrypta, methyl-Trypta; MMTrypta, dimethyl-Trypta; IndolAc, indole-3-acetaldoxime; 5HFKyn, 5-
hydroxy-N-formylkynurenine; 5HKyn, 5-hydroxy-kynurenine; 5HKynN, 5-hydroxykynuramine; 
DHQuin, 4,6-dihydroxy-quinoline; 5HAc, 5-hydroxy-indoleacetaldehyde; F5Hkyn, formyl-5-
hydroxykynurenamine; NMSer, N-methyl-serotonin; NAcSet, N-acety-serotonin; IndolP, indole-
pyruvat. The abbreviations of the enyzme are as follows: TDO, tryptophan 2,3-dioxygenase; IDO, 
indoleamine 2,3-dioxygenase; AFMID, arylformamidase; KMO,  kynurenine 3-
monooxygenase; KYNU, kynureninase; KAT, kynurenine  transaminase; HAAO, 3-
hydroxyanthranilic acid oxidase; ACMSD, Acms-decarboxylase; QPRT, quinolinic acid 
phosphoribosyltransferase; TPH, tryptophan-5-monooxygenase; DDC, aromatic-L-amino-acid 
decarboxylase; IL4I1, interleukin 4 induced 1; AANAT, arylalkylamine N-acetyltransferase; ASMT, 
acetylserotonin N-methyltransferase; MAOA/B, monoamine oxidase A/B; IMNT, tryptamine N-
methyltransferase; WARS, tryptophanyl-aminoacyl-tRNA-synthetase.  The abbreviations of the 
transporters are as follows: SLC7A5, Large neutral amino acids transporter small subunit 1; 
SLC7A8, Large neutral amino acids transporter small subunit 2. 
FIGURE 2 
Predicted flux distribution in brain and liver. For simplicity only the main metabolic compounds and 
reactions of the serotonin and kynurenine pathways are shown. The width of the arrow shades 
represents the predicted flux relative to tryptophan inflow. Relative fluxes and metabolite 
concentrations are indicated. A tryptophan concentration of 5µM was used for all simulations 
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presented in this figure to allow tissue comparison. See legend to Figure 1 for abbreviations. A) Rat 
liver B) Rat cortex C) Human liver D) Human brain. 
FIGURE 3 
Predicted flux control is different between liver and brain. Flux through DDC in the serotonin 
pathway and HAAO were used as measures of fluxes in the serotonin pathway and kynurenine 
pathway, respectively. A bar plot is added next to the reactions that have a control coefficient of more 
than +0.1 or less than -0.1. The bar is black for control of flux through HAAO (kynurenine pathway) 
and grey for control of flux through DDC (serotonin pathway). The interval between the tics on the y-
axis is 0.5. The distribution of flux control is different between A) human liver and B) human brain. 
FIGURE 4 
Simulation of the influence of liver metabolism on brain kynurenine metabolites. A) Percentage change 
of selected metabolite concentrations calculated in the combined brain-liver model relative to the 
isolated brain model. B) Changes in brain L-kyn concentrations, and C) changes in Quin 
concentrations upon reduction of liver KMO activity to 10%. The simulation results are presented as a 
range of concentrations because the reported range of free tryptophan (4-16 µM, see Table 2) was used 
as input for the model. The calculated values are compared to measurements reported by Zwilling et 
al. (39).  
FIGURE 5 
Simulation of changes in the tryptophan pathway in brain cancer. Using expression data from a brain 
cancer study by Grzmil et al. (40) we simulated intermediate concentrations of A) tryptophan and B) 
L-Kyn for healthy brain, primary glioblastoma and secondary glioblastoma. For each patient a separate 
model was generated resulting in individual intermediate concentrations. The tryptophan concentration 
used as input for the model was 5µM. To show the variance between the samples, distribution of the 
concentrations was plotted. The central mark is the median, the edges of the box are the 25th and 75th 
percentiles, thus whiskers extend to the most extreme data points not considered to be outliers, outliers 
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